Ms. Williams-Brinkley brings more than 35 years of executive leadership experience in healthcare to the Travere Board
SAN DIEGO, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the appointment of Ruth Williams-Brinkley to the Company’s Board of Directors, effective immediately. Ms. Williams-Brinkley brings to Travere more than 35 years of executive leadership in care delivery and health plan operations.
“On behalf of the Board of Directors, I am pleased to welcome Ruth to Travere,” said Gary Lyons, chairman of the Travere Therapeutics Board of Directors. “She is a distinguished leader with extensive experience in the delivery of care and is an actively engaged and admired community leader. As we look to future potential commercial launches from our pipeline, Ruth’s insights will be instrumental in achieving our goal of enabling broad access to our innovative therapies.”
Ms. Williams-Brinkley added: “This is an exciting time to join the board of Travere as the organization advances towards delivering new treatment options for people living with rare kidney conditions, many of whom have been significantly underserved for decades. I am proud to be joining a company that cares deeply about the patients and caregivers it serves, and is a champion for diversity, health equity and inclusion in the rare disease community.”
Ms. Williams-Brinkley has served as President of the Kaiser Foundation Health Plan for the Mid-Atlantic States since 2020, overseeing all of Kaiser Permanente’s care delivery and health plan operations in Washington, D.C., and suburban Maryland, Baltimore, and Northern Virginia. Kaiser Permanente’s Mid-Atlantic States region operates 34 medical offices and has 789,030 members. She joined Kaiser Permanente in 2017 as President of Kaiser Foundation Health Plan and Hospitals of the Northwest, in Portland, Oregon. Prior to her roles at Kaiser Permanente, Ms. Williams-Brinkley served as CEO of KentuckyOne Health, Kentucky’s largest integrated health system. KentuckyOne was a division of CommonSpirit Health, one of the nation’s largest nonprofit health systems. Before joining KentuckyOne Health, Ms. Williams-Brinkley served as president and CEO of Carondelet Health Network in Tucson, Arizona, and as president and CEO of Memorial Healthcare System in Chattanooga, Tennessee.
Ms. Williams-Brinkley has repeatedly appeared on Modern Healthcare’s “Top 25 Women in Healthcare” and “Top 25 Minority Executives in Healthcare” lists, and she was named by Modern Healthcare as one of “2020's 100 Most Influential People”. In addition, Ms. Williams-Brinkley has been named one of Becker’s Hospital Review’s “Most Admired CEOs”. Ms. Williams-Brinkley serves on the not-for-profit Boards of DePaul University in Chicago, Illinois and the Clinical Center Research Hospital Board of the National Institutes of Health (NIH) in Washington, D.C., as well as on the Board of Directors of University of Phoenix. She holds a bachelor’s degree and a master’s of science degree in nursing from DePaul University, and she has an honorary doctoral degree from Spaulding University, Louisville, Ky. Ms. Williams-Brinkley is also a Fellow of the American College of Healthcare Executives (FACHE).
About Travere Therapeutics
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com
Forward Looking Statements
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, these statements are often identified by the words "may", "might", "believes", "thinks", "anticipates", "plans", "expects", "intends" or similar expressions. In addition, expressions of our strategies, intentions or plans are also forward-looking statements. Such forward-looking statements include, but are not limited to, references to future potential commercial launches from the Company’s pipeline and the Company’s ability to achieve its goal of enabling broad access to its innovative therapies. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the regulatory review and approval process, including the Subpart H accelerated approval pathway in the United States and the conditional marketing authorization (CMA) pathway in Europe. Specifically, the Company faces the risk that the Phase 3 DUPLEX Study of sparsentan in FSGS will not demonstrate that sparsentan is safe or effective or serve as a basis for accelerated approval of sparsentan as planned; risk that the Phase 3 PROTECT Study of sparsentan in IgAN will not demonstrate that sparsentan is safe or effective or serve as the basis for accelerated approval of sparsentan as planned; and risk that sparsentan will not be approved for efficacy, safety, regulatory or other reasons, and for each of the Company’s programs, risk associated with enrollment of clinical trials for rare diseases and risk that ongoing or planned clinical trials may not succeed or may be delayed for safety, regulatory or other reasons. The Company faces risk that it will be unable to raise additional funding that may be required to complete development of any or all of its product candidates; risk relating to the Company's dependence on contractors for clinical drug supply and commercial manufacturing; uncertainties relating to patent protection and exclusivity periods and intellectual property rights of third parties; risks associated with regulatory interactions; and risks and uncertainties relating to competitive products, including current and potential future generic competition with certain of the Company’s products, and technological changes that may limit demand for the Company's products. The Company faces additional risks associated with the potential impacts the COVID-19 pandemic may have on its business, including, but not limited to (i) the Company’s ability to continue its ongoing development activities and clinical trials, (ii) the timing of such clinical trials and the release of data from those trials, (iii) the Company’s and its suppliers’ ability to successfully manufacture its commercial products and product candidates, and (iv) the market for and sales of its commercial products. You are cautioned not to place undue reliance on these forward-looking statements as there are important factors that could cause actual results to differ materially from those in forward-looking statements, many of which are beyond our control. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Investors are referred to the full discussion of risks and uncertainties as included in the Company's most recent Form 10-Q, Form 10-K and other filings with the Securities and Exchange Commission.
Chris Cline, CFA
Senior Vice President, Investor Relations & Corporate Communications